Sangamo BioSciences To Present Data From ZFP Therapeutic Programs At Annual Meeting Of The American Society Of Hematology Five Presentations Include Non-Human Primate Data from Sangamo's In Vivo Protein Replacement Platform™ Approach for Hemophilia B, and Data from ZFN-Mediated Genome Editing Approach for Hemoglobinopathies

RICHMOND, Calif., Nov. 5, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that non-human primate data from its proprietary In Vivo Protein Replacement Platform (IVPRP™) program for hemophilia B, and data from its ZFP Therapeutic® hemoglobinopathy programs in collaboration with Biogen, will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH). The 2015 ASH meeting will be held in Orlando, FL from December 5-8, 2015. "Our presentations at this year's ASH meeting highlight the breadth of our highly specific genome editing platform in both in vivo and ex vivo therapeutic...